Desferrithiocin analogue uranium decorporation agents

References

• Anderegg G, Räber M. Metal complex formation of a new siderophore desferrithiocin and of three related ligands. Journal of the Chemical Society, Chemical Communications 1990; 1194–1196
   Google Scholar
• Bergeron R J, Streiff R R, Creary E A, Daniels R D, Jr, King W, Luchetta G, Wiegand J, Moerker T, Peter H H. A comparative study of the iron-clearing properties of desferrithiocin analogues with desferrioxamine B in a Cebus monkey model. Blood 1993; 81: 2166–2173
   PubMed Web of Science ®Google Scholar
• Bergeron R J, Streiff R R, Wiegand J, Vinson J RT, Luchetta G, Evans K M, Peter H, Jenny H B. A comparative evaluation of iron clearance models. Annals of the New York Academy of Sciences 1990; 612: 378–393
   PubMed Web of Science ®Google Scholar
• Bergeron R J, Wiegand J, Bharti N, Singh S, Rocca J R. Impact of the 3,6,9-trioxadecyloxy group on desazadesferrithiocin analogue iron clearance and organ distribution. Journal of Medicinal Chemistry 2007; 50: 3302–3313
   PubMed Web of Science ®Google Scholar
• Bergeron R J, Wiegand J, Dionis J B, Egli-Karmakka M, Frei J, Huxley-Tencer A, Peter H H. Evaluation of desferrithiocin and its synthetic analogues as orally effective iron chelators. Journal of Medicinal Chemistry 1991; 34: 2072–2078
   PubMed Web of Science ®Google Scholar
• Bergeron R J, Wiegand J, McManis J S, Bharti N. The design, synthesis, and evaluation of organ-specific iron chelators. Journal of Medicinal Chemistry 2006a; 49: 7032–7043
   PubMed Web of Science ®Google Scholar
• Bergeron R J, Wiegand J, McManis J S, Bharti N, Singh S. Design, synthesis, and testing of non-nephrotoxic desazadesferrithiocin polyether analogues. Journal of Medicinal Chemistry 2008; 51: 3913–3923
   PubMed Web of Science ®Google Scholar
• Bergeron R J, Wiegand J, McManis J S, Bussenius J, Smith R E, Weimar W R. Methoxylation of desazadesferrithiocin analogues: Enhanced iron clearing efficiency. Journal of Medicinal Chemistry 2003; 46: 1470–1477
   PubMed Web of Science ®Google Scholar
• Bergeron R J, Wiegand J, McManis J S, McCosar B H, Weimar W R, Brittenham G M, Smith R E. Effects of C-4 stereochemistry and C-4′ hydroxylation on the iron clearing efficiency and toxicity of desferrithiocin analogues. Journal of Medicinal Chemistry 1999a; 42: 2432–2440
   PubMed Web of Science ®Google Scholar
• Bergeron R J, Wiegand J, McManis J S, Vinson J RT, Yao H, Bharti N, Rocca J R. (S)-4,5-dihydro-2-(2-hydroxy-4-hydroxyphenyl)-4-methyl-4-thiazolecarboxylic acid polyethers: A solution to nephrotoxicity. Journal of Medicinal Chemistry 2006b; 49: 2772–2783
   PubMed Web of Science ®Google Scholar
• Bergeron R J, Wiegand J, Weimar W R, Vinson J RT, Bussenius J, Yao G W, McManis J S. Desazadesmethyldesferrithiocin analogues as orally effective iron chelators. Journal of Medicinal Chemistry 1999b; 42: 95–108
   PubMed Web of Science ®Google Scholar
• Brittenham G M. Pyridoxal isonicotinoyl hydrazone (PIH): Effective iron chelation after oral administration. Annals of the New York Academy of Sciences 1990; 612: 315–326
   PubMed Web of Science ®Google Scholar
• Chiappini R, Taillade J M, Brebion S. Development of a high sensitivity ICP-MS for actinide measurement in the femtogram range. Journal of Analytical Atomic Spectrometry 1996; 11: 497–503
   Web of Science ®Google Scholar
• Craft E S, Abu-Qare A W, Flaherty M M, Garofolo M C, Rincavage H L, Abou-Donia M B. Depleted and natural uranium: Chemistry and toxicological effects. Journal of Toxicology and Environmental Health Pt B 2004; 7: 279–317
   Web of Science ®Google Scholar
• Domingo J L, Colomina M T, Llobet J M, Jones M M, Singh P K, Campbell R A. The action of chelating agents in experimental uranium intoxification in mice: Variations with structure and time of administration. Fundamental and Applied Toxicology 1992; 19: 350–357
   PubMedGoogle Scholar
• Domingo J L, Ortega A, Llobet J M, Corbella J. Effectiveness of chelation therapy with time after acute uranium intoxication. Fundamental and Applied Toxicology 1990; 14: 18–95
   Google Scholar
• Donnadieu-Claraz M, Bonnehorgne M, Dhieux B, Maubert C, Cheynet M, Paquet F, Gourmelon P. Chronic exposure to uranium leads to iron accumulation in rat kidney cells. Radiation Research 2007; 167: 454–464
   PubMed Web of Science ®Google Scholar
• Durbin P W, Kullgren B, Ebbe S N, Xu J, Raymond K N. Chelating agents for uranium(VI): 2. Efficacy and toxicity of tetradentate catecholate and hydroxypyridinonate ligands in mice. Health Physics 2000; 78: 511–521
   PubMed Web of Science ®Google Scholar
• Exjade Prescribing Information. 2007, [Online]. Accessed from the website: http://www.pharma.us.novartis.com/product/pi/pdf/exjade.pdf
   Google Scholar
• Gorden A E, Xu J, Raymond K N, Durbin P. Rational design of sequestering agents for plutonium and other actinides. Chemical Reviews 2003; 103: 4207–4282
   PubMed Web of Science ®Google Scholar
• Gueguen Y, Souidi M, Baudelin C, Dudoignon N, Grison S, Dublineau I, Marquette C, Voivin P, Gourmelon P, Aigueperse J. Short-term hepatic effects of depleted uranium on xenobiotic and bile acid metabolizing cytochrome P450 enzymes in the rat. Archives of Toxicology 2006; 80: 187–195
   PubMed Web of Science ®Google Scholar
• Hahn F E, McMurry T J, Hugi A, Raymond K N. Coordination chemistry of microbial iron transport. 42. Structural and spectroscopic characterization of diastereomeric Cr(III) and Co(III) complexes of desferriferrithiocin. Journal of the American Chemical Society 1990; 112: 1854–1860
   Web of Science ®Google Scholar
• Hengé-Napoli M H, Ansoborlo E, Houpert P, Mirto H, Paquet F, Burgada R, Hodgson S, Stradling G N. Progress and trends in in vivo chelation of uranium. Radiation Protection Dosimetry 1998; 79: 449–452
   Web of Science ®Google Scholar
• Hengé-Napoli M H, Archimbaud M, Ansoborlo E, Metivier H, Gourmelon P. Efficacy of 3,4,3-LIHOPO for reducing the retention of uranium in rat after acute administration. International Journal of Radiation Biology 1995; 68: 389–393
   PubMed Web of Science ®Google Scholar
• Hoffbrand A V, Al-Refaie F, Davis B, Siritanakatkul N, Jackson B FA, Cochrane J, Prescott E, Wonke B. Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients. Blood 1998; 91: 295–300
   PubMed Web of Science ®Google Scholar
• Kemble J V. The new chelating agent Ca-DTPA in the treatment of primary haemochromatosis. Guys Hospital Report 1964; 113: 68–73
   PubMedGoogle Scholar
• Levien T, Baker D E. Pentetate calcium trisodium (Ca-DTPA) and pentetate zinc trisodium (Zn-DTPA). Formulary Drug Reviews 2005; 40: 65–71
   Google Scholar
• Naegeli H-U, Zähner H. Metabolites of microorganisms. Part 193. Ferrithiocin. Helvetica Chimica Acta 1980; 63: 1400–1406
   Web of Science ®Google Scholar
• Olivieri N F. Long-term therapy with deferiprone. Acta Haematologica 1996; 95: 37–48
   PubMed Web of Science ®Google Scholar
• Olivieri N F, Brittenham G M, McLaren C E, Templeton D M, Cameron R G, McClelland R A, Burt A D, Fleming K A. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. New England Journal of Medicine 1998; 339: 417–423
   PubMed Web of Science ®Google Scholar
• Paquet F, Chazel V, Houpert P, Guilmette R, Muggenburg B. Efficacy of 3,4,3-LI(1,2-HOPO) for decorporation of Pu, Am and U from rats injected intramuscularly with high-fired particles of MOX. Radiation Protection Dosimetry 2003; 105: 521–525
   PubMed Web of Science ®Google Scholar
• Paquet F, Montegue B, Ansoborlo E, Henge-Napoli M H, Houpert P, Durbin P W, Raymond K. Efficacy of 3,4,3-L1HOPO for reducing neptunium retention in the rat after simulated wound contamination. International Journal of Radiation Biology 2000; 76: 113–117
   PubMed Web of Science ®Google Scholar
• Pentetate Calcium Trisodium Injection Package Insert – Instruction for Use. 2008, [Online]http://www.akorn.com/documents/pentatate/product_info/ca_dtpa_insert.pdf
   Google Scholar
• Pippard M J, Jackson M J, Hoffman K, Petrou M, Modell C B. Iron chelation using subcutaneous infusions of diethylene triamine penta-acetic acid (DTPA). Scandinavian Journal of Haematology 1986; 36: 466–472
   PubMedGoogle Scholar
• Powell L W, Thomas M J. Use of diethylenetriamine penta-acetic acid (DTPA) in the clinical assessment of total body iron stores. Journal of Clinical Pathology 1967; 20: 896–904
   PubMed Web of Science ®Google Scholar
• Richardson D R. The controversial role of deferiprone in the treatment of thalassemia. Journal of Laboratory and Clinical Medicine 2001; 137: 324–329
   PubMed Web of Science ®Google Scholar
• Sangster J. Octanol-water partition coefficients: Fundamentals and physical chemistry. John Wiley and Sons, ChichesterUK 1997
   Google Scholar
• Voegtlin C, Hodge H C. Pharmacology and toxicology of uranium compounds, with a section on the pharmacology and toxicology of fluorine and hydrogen fluoride. McGraw-Hill Book Co, New York 1949
   Google Scholar
• Wolfe L C, Nicolosi R J, Renaud M M, Finger J, Hegsted M, Peter H, Nathan D G. A non-human primate model for the study of oral iron chelators. British Journal of Haematology 1989; 72: 456–461
   PubMed Web of Science ®Google Scholar
• Xu J, Raymond K N. Uranyl sequestering agents: Correlation of properties and efficacy with structure for UO22+ complexes of linear tetradentate 1-methyl-3-hydroxy-2(1H)-pyridinone ligands. Inorganic Chemistry 1999; 38: 308–315
   Web of Science ®Google Scholar